Protocol Ledger

Biopharma Industry · Consolidated Sponsor Hub

Sumitomo Pharma America: Clinical Trials & FDA Approval Profile

Sumitomo Pharma America (Global / Institutional) sponsors 15 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 5 active protocols (5 recruiting now), 3 completed protocols, and 0 all-time original FDA Drugs@FDA NDA and BLA approvals.

Primary Focus: Oncology and Hematology Interactive Workbench: Open Full Annual Timeline & Compare ->
Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)46.7%
Median Closed Enrollment vs National (145 pts)50 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for Sumitomo Pharma America
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)15
Active Pipeline (Recruiting Now)5 (5)
Completed vs Stopped Early3 / 7 (46.7%)
Median Closed Actual Enrollment50 participants
Physical Hospital Site Disclosure99.8% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals0 (0 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With Sumitomo Pharma America
Hospital Research SiteLocationShared Protocols
Ohio State University Comprehensive Cancer CenterColumbus, OH4
Columbia University Irving Medical CenterNew York, NY4
Vanderbilt University Medical CenterNashville, TN3

Indexed Multi-Center Phase II & III Protocols

Representative ClinicalTrials.gov v2 Studies Sponsored by Sumitomo Pharma America
NCT IdentifierProtocol Brief TitlePhaseStatus
NCT03969420Study of Alvocidib in Patients With Relapsed/Refractory AML Following Treatment With Venetoclax Combination TherapyPhase IITERMINATED
NCT05227209A Clinical Trial to Determine the Long-term Safety and Tolerability of an Investigational Drug in People With Major Depressive Episode AssocPhase IIITERMINATED

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Sumitomo Pharma America across sibling Meru public-data platforms.

Explore interactive annual charts and M&A subsidiary rollups in the Sumitomo Pharma America Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI